XNAS · Healthcare · Biotechnology
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -1.11 | -1.24 | -11.71% | $0 | ❌ Miss | +2.16% | -19.35% | — |
| 2026-03-31 | Q4 2025 | -1.26 | -1.45 | -15.08% | $0 | ❌ Miss | +0.93% | +1.04% | +2.93% |
| 2025-11-14 |
| Q3 2025 |
| -1.06 |
| -0.99 |
| +6.60% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-03-31 | Q4 2024 | -2.74 | -1.18 | +56.93% | $0 | ✅ Beat | -4.25% | -31.19% | -5.93% |
| 2024-11-14 | Q3 2024 | -7.12 | -4.54 | +36.24% | $0 | ✅ Beat | +4.66% | +180.29% | +239.78% |
| 2024-08-14 | Q2 2024 | -4.25 | -6.75 | -58.82% | $0 | ❌ Miss | -20.51% | -15.13% | -25.33% |
| 2024-05-13 | Q1 2024 | — | -4.00 | — | $0 | — | -4.23% | -14.49% | -19.72% |
| 2024-03-18 | Q4 2023 | — | -1.00 | — | $0 | — | — | — | — |
Showing last 8 quarters.